Roche Holding AG (RHHBY) announced positive results from a late-stage clinical trial of its breast cancer drug combination, which includes the company's novel breast cancer treatment giredestrant. The trial successfully achieved its primary endpoint, demonstrating significant improvement in progression-free survival, which drove Roche shares up 1.5%.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.